FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to pharmaceutical compositions containing d4-domperidone formula (I)
(I)
or a pharmaceutically acceptable salt thereof. The formulations also contain (i) glyceryl stearate and medium chain triglyceride; or (ii) a stearoyl polyoxyl glyceride, a nonionic polymer polyethylene oxide, and a medium chain triglyceride; or (iii) non-ionic polymer polyethylene oxide and polyethylene glycol. The invention also relates to methods for treating a disorder that is gastroparesis, vomiting independent of gastroparesis, nausea associated with gastroparesis, vomiting associated with gastroparesis, gastroesophageal reflux disease, insufficient lactation, or a combination thereof, including administering to the patient the composition described herein. In some aspects, the disorder is gastroparesis. In other aspects, the disorder is a gastrointestinal reflux disease. In the following aspects, the disorder is insufficient lactation.
EFFECT: obtaining pharmaceutical compositions containing d4-domperidone.
34 cl, 5 ex, 16 tbl, 12 dwg
Title | Year | Author | Number |
---|---|---|---|
CAPSULES WITH SOLUBLE OESTRADIOL FOR INTRAVAGINAL INTRODUCTION | 2013 |
|
RU2740059C2 |
PHARMACEUTICAL COMPOSITIONS AND METHODS BASED ON OESTRADIOL FOR INTRAVAGINAL INTRODUCTION | 2014 |
|
RU2713888C2 |
MODIFIED RELEASE PHARMACEUTICAL COMPOSITION | 2009 |
|
RU2495666C2 |
FORMULATIONS FOR ORAL ADMINISTRATION OF DRUG PREPARATIONS AND RELATED METHODS | 2008 |
|
RU2485975C2 |
NEW COMPOSITIONS AND METHODS | 2018 |
|
RU2767410C2 |
STABLE COMPOUNDS OF UNDECANOATE TESTOSTERONE | 2015 |
|
RU2708238C2 |
CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS FOR TREATING CONGENITAL ADRENAL HYPERPLASIA | 2019 |
|
RU2824490C2 |
ORAL FORMULATIONS CONTAINING CYTIDINE ANALOGUES, AND METHODS FOR USING THEM | 2009 |
|
RU2476207C2 |
ORAL COMPOUNDS CONTAINING CYTIDINE ANALOGUES AND METHODS FOR USE THEREOF | 2018 |
|
RU2765076C2 |
NEW IMPROVED COMPOSITION CONTAINING AT LEAST ONE CADOTRIL | 2017 |
|
RU2751772C2 |
Authors
Dates
2023-05-25—Published
2019-10-25—Filed